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Summary
Fresh peripheral blood mononuclear cells exposed to alloantigen for 3-8 d in the presence of
anti-CD3 antibodies showed no response after restimulation with cells from the original donor
but remained capable of responding to third-party donors. Antigen-specific nonresponsiveness
was induced by both nonmitogenic and mitogenic anti-CD3 antibodies but not by antibodies
against CD2, CD4, CD5, CD8, CD18, or CD28. Nonresponsiveness induced by anti-CD3
antibody inmixedleukocyte culturewas sustainedforat least 34dfrom initiation ofthe culture
and 26 d after removal of the antibody. Anti-CD3 antibody also induced antigen-specific non-
responsiveness in cytotoxic T cell generation assays. Anti-CD3 antibody did not induce non-
responsiveness in previously primed cells. Nonresponsiveness inducedby anti-CD3didnotappear
tobeassociated with suppressor cellactivation. Thus, co-stimulation oftheT cellreceptor-CD3
complex on unprimed T cells with a fluid phase anti-CD3 antibody and allogeneic major
histocompatibility complex antigens can induce either clonal anergy or clonal deletion. These
results suggest novel approaches for achieving transplantation tolerance.
Antigen recognitionby human T cells is mediated by the
1-1ciandS polymorphicchains oftheTCR, noncovalently
associated on the cell surface with a group offive invariant
polypeptides designated -y,S,e, and ~-r, which collectively
represent the CD3 complex responsible for signal transduc-
tion (1). Bindingofan antibody to TCRor to CD3 canblock
T cell responses not merely by steric hindrance ofTCR but
alsobyalteringcellularfunction (2, 3). TheeffectsofTCRCD3
binding by an antigen presented by an MHC gene product,
a physiological solid-phase ligand, differ substantially from
theeffectsofbindingbyafluidphaseligand, suchasa soluble
antibody (4). Anincrease intheconcentration ofcytoplasmic
freecalcium and activation ofprotein kinase C can occur in
either case, but Ilr2 receptor expression isinducedonlywith
solid-phaseligands(4-6). Activation oftheIIr2 generequires
TCRCD3 bindingby a solid-phaseligand together withcer-
tain other signals provided by accessory cells (7, 8). Soluble
factorssuch asIIrl andcell-cellinteractions mediated through
CD2, CD5, CD28, LFA1, and MHC class I molecules can
function as accessoryactivation signals (7-9). In the absence
ofsuch signals, it has been observed in type I murine T cell
clones that solid-phasebinding toTCRCD3 inducesanergy
to further stimulationby specific antigen (reviewedin refer-
ences 10, 11) and IIr2 (12).
Afterbinding offluidphaseantibody, the TCRCD3-ligand
complexundergoesreceptor-mediatedendocytosis (4, 13, 14),
but after binding of a solid-phase ligand internalization of
the TCRCD3 complex does not occur. The process ofin-
ternalization, also referredtoas modulation, is energy-depen-
dent and appears tobe regulated by the state ofphosphoryla-
tionofthe CD3,y subunit(15). AfterTCRCD3modulation,
T cellsbecome refractory to restimulation with specific an-
tigen, PHA, Con A, or to signals delivered through CD2,
CD5, andCD28 (4, 16-18). Reappearance ofresponsiveness,
however, parallelsreexpression ofTCR-CD3 on the cell sur-
face (16). In this report, we demonstratethatco-stimulation
ofunprimed humanTcellswith soluble anti-CD3 antibody
andallogeneic MHC caninduce a sustainedstate ofantigen-
specific nonresponsiveness.
Materials and Methods
PrimaryMixedLeukocyteCulture
￿
PBMC were prepared by den-
sity gradient centrifugation on Ficoll-Hypaque. PBMC were
resuspended in medium containing RPMI 1640, 25 mM Hepes,
1 U/ml penicillin, 1 jig/ml streptomycin, and 10% pooled human
serum that hadbeen heat inactivated at 56°C for30 min.Responder
A and stimulators B and C were unrelated individuals chosen so
that there was at leastone HLAclass I and one HLA-DR antigen
mismatched betweenAandB, andAandC. Stimulator cell donors
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responder cells were mixedwith 5 x 104 irradiated stimulator cells
(3,000 rad) in round-bottomed 96-well plates. In certain experi-
ments antibody containing medium was dispensed first, followed
in sequence by responc]cr ahd stimulator cells. Plates were cultured
at 37°C in a 5% C02 atmosphere. Assays were performed in
triplicate. Cultures were pulsed with one WCi of [3H]thymidine
18 h before harvesting. 10 replicate plates were setup andone was
harvested each day for 10 consecutive days. Data are reported as
mean counts per minute of the three replicates.
Restimulation Assays. 10' PBMC from one individual were
primed with an equivalent number of irradiated (3,000 rad) PBMC
from another HLA class I andII incompatible individual in 25-cmz
flasks, using identical medium and culture conditions as for pri-
mary MLC carried out in 96-well plates. Cells were cultured for
12 d before harvesting unless specified otherwise. Forblocking ex-
periments, cells were cultured for 8 d in thepresence of antibody,
washed three times, recultured in medium without antibody for
four additional days, harvested on day 12, and then restimulated.
In experiments oftertiary stimulation, asecondaryculture wascar-
ried out in flask, as in the first. For assay, 2 x 104primed respon-
ders and 5 x 104 irradiated stimulators were incubated in 96-well
round-bottomed wells in medium without antibody. Assays were
performed as detailed forprimary MLC. Percent control response
of antibody-treated cellswas calculated by theformula: 100 x [cpm
(CIE) - cpm (QE)]/[cpm (ac) - cpm (I0c)], where: a is allogeneic
MLR, /3 is autologous MLR, E is experimental antibody, and C
is control antibody.
Suppression Assays.
￿
Lymphocytes were primed as described for
usein restimulation assays. On day 12, primed cellswere irradiated
with 1,500 rad and tested as regulators in a primary MLC. 10^
regulators were mixed with 5 x 104 fresh autologous responder
PBMC and 5 x 104 irradiated (3,000 rad) stimulators per well.
Proliferation was measured daily for 10 d. Theresponse to irradi-
ated autologous stimulators wasconsistently <2% oftheresponse
of allogeneic stimulators andwasnot affected by primed regulators.
Percent inhibition was calculated by theformula: 100 x
￿
[cpm
(responder +
￿
stimulator,; + regulator.)]/ [cpm (responder +
stimulator.)]
Generation ofCTL.
￿
Freshly separated PBMC or primed lym-
phocytes were tested for CTL precursor activity by priming in a
modified MLC. Responder cells (107) either fresh or primed as
specified for each experiment, and irradiated stimulator cells (107),
were cultured for6d, harvested, washed twice, and tested forcyto-
lytic effector activity in a 4-h "Cr-release assayagainst PHAblasts.
Both autologous or stimulator lymphocytes were tested as target
cells. Maximum and spontaneous release values were obtained by
incubating targetswith 1% Triton-X 100andmedium alone, respec-
tively.Triplicate assays were carried out at E/Tratio of 10:1, 50:1,
100:1 in V-bottomed 96-well plates. Data are reported as mean per-
cent specific "Cr release.
Antibodies.
￿
Murine mAbs used in this studyare listed in Table
1. Antibodies WT31(anti-CD3-a/0 complex), X39andX40(anti-
KLH), and 2A3 (anti-CD25) were obtained from Becton Dick-
inson (San Jose, CA). Antibodies 1A12 and Tl1D7 (Anti-murine
Thy-1.1) were kindly provided by Dr. Irv Bernstein (Fred Hutch-
inson Cancer Research Center, Seattle, WA). All other antibodies
were produced in ourlaboratory and were previously described(see
references 19-28 cited in Table 1) with the exception of two of
them. Antibodies BC3 andBC18 areproducts ofhybridomas gener-
ated by fusion of the HGPRT- myeloma cell line BALB/c
MOPC21 NSi/1 provided by Dr. Caesar Milstein (Molecular Re-
search Council, Cambridge, UK) with splenocytes obtained from
* See Materials and Methods.
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BALB/c mice after multiple intraperitoneal immunizations with
2 x 106 PHA-stimulated mononuclear cells from normal human
volunteers. The specificity of antibody BC3 for CD3 was deter-
minedby immunoprecipitating two distinct species of 19,000 and
29,000 Mfrom t'II-labeled PBL andby comodulation experiments
with anti-CD3 antibody 64.1 (20). Antibody BC3 specificity for
the CD3E subunit was documented by staining of the EAC2 cell
line (kindly provided by Dr. Ellis Reinherz, Dana Farber Cancer
Institute, Boston, MA), which was generated by transfecting the
human CD3E cDNA into the 3DO54.8 murine T cell line (29).
In contrast to antibody BC3, the anti-CD3 antibody 38.1 did not
bind eAC2, suggesting that it recognizes another CD3 subunit
or an epitope on theE chainnot expressedby thetransfectant. The
anti-CD3 antibody 64.1 demonstrated very weak bindingto EOC2.
Antibody BC3 blockedbinding of FITC-conjugated antibody 64.1
or 38.1 to human Tcells, butneither 64.1 nor38.1 blockedbinding
of FITC-conjugated BC3. Finally, antibody 64.1 blocked binding
ofFITC-conjugated38.1 to human Tcells, but thereversedid not
occur. Takentogether, thesedata suggest that BC3, 64.1, and38.1
bind to closely associated but distinct epitopes expressed on the
CD3 complex. The specificity of antibody BC18 for CD2 was
determined by immunoprecipitating a 50,000 M species from
"6I-labeled PBMC and by blocking lymphocyte adhesion to sheep
erythrocytes. Before usein functional studies, mAbs were purified
from ascites fluids by precipitation with 50% saturatedammonium
sulfate followed by DEAE-Sephacryl chromatography (Pharmacia
Fine Chemicals, Piscataway, NJ) or by affinity chromatography on
Sepharose-bound protein A. Purified antibodies were dialyzed
against PBS and filter sterilized.
Immunofluorescence Analyses.
￿
Surface expression of the CD3
complex or the CD3-associated TCR-a/0 complex was quanti-
Table 1. mAbs Used in this Study
Clone Antigen
designation Ig subclass recognized Reference
9.6 IgG2a CD2 19
BC18 IgG1 CD2 This paper
38 .1 IgM CD3 20
64.1 IgG2a CD3-E 20
BC3 IgG2b CD3-E This paper
WT31 IgGI CD3-a//3 complex 21
66 .1 IgM CD4 20
10.2 IgG2a CD5 22
51 .1 IgG2a CD8 23
60.3 IgG2a CD18 24
2A3 IgG1 CD25 25
9.3 IgG2a CD28 26
X40 IgGI KLH
X39 IgG2a KLH
9138 IgG2a p15(E) 27
1A12 IgG2b Thyl 28
TllD7 IgM Thyl 28PRIMARY MLR : RESPONDER A
ANTIBODY ADDED
SECONDARY MLR : RESPONDER A PRIMED TO B
ANTIBODY WASHED
_. ,
￿
Stimulator C
Antibody:
* mAbcontrol
o mAb CD3
Figure 1.
￿
Inductionofantigenspecific nonresponsiveness by anti-CD3.
Fortheprimary MLR, 50,000 respondercells from donorAwere stimu-
lated with 50,000 irradiated stimulator cells from donorB (top left panel)
anddonor C (top rightpanel) in thepresence of anti-CD3 antibody BC3
(open square) or a nonbinding control antibody (closed square). The cpm
of cultured cells incubated with autologous stimulator cells with BC3
or control antibody were not different from each other and both were
<2% of the response to allogenric stimulators in the presence of control
antibody (not shown). For the secondary MLR, responders from donor
Aprimed with cells from donorB in thepresence of BC3 (open square)
or control antibody (closedsquare) were restimulated with cellsfrom donor
B(left bottompanel) and C (right bottom panel) in the absence of antibody.
100 101 102 103 104
Fluorescence Intensity -
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tated by microfluorimetry ofcellsstained respectively with FITC-
conjugated antibody BC3 (conjugated with themethod ofGoding
[30]) or with FITC-conjugated antibody WT31 (purchased from
Becton Dickinson). Controls were provided by cells stained with
isotype-matched antibodies ofirrelevant specificity. Cells (5 x 105)
were incubated at 4°C for 30 min in 25 lrl of medium containing
0.1%sodium azideandasaturating concentration ofantibody. Cells
were then washed, fixed in 1% paraformaldehyde, and analyzed
on a FACScan using C30 software (Becton Dickinson).
Results
Induction ofAntigen-specfic Nonresponsiveness by Anti-CD3.
Fresh human PBMC were incubated for 1 h at 37°C with
10,ug/ml of either the anti-CD3 murine IgG2b mAb BC3
or a nonbinding antibody of irrelevant specificity. The
antibody-treated PBMC were then mixed with irradiated,
HLA-incompatible stimulator cells and cultured in the con-
tinuous presence of antibody. Antibody BC3 did not induce
proliferation ofcells cultured with irradiated autologous stimu-
lators (data not shown) and inhibited completely the prolifer-
ative response of cells stimulated with allogeneic stimulators
from two different donors (Fig. 1, top panels). To evaluate
effect o£ antibody BC3 on secondary responses, lymphocytes
were cultured with alloantigen for 8 d in separate flasks in
medium containing BC3 or control antibody. Cells were then
washed to remove antibody, cultured in fresh medium for
an additional 4 d to allow reexpression ofthe CD3-TCR com-
plex (as demonstrated in Fig. 2), and then restimulated with
irradiated PBMC from either the original donor (Fig. 1, left
bottom pane or from a third-party donor (Fig. 1, rightbottom
pane in medium containing no antibody. Cells primed in
the presence of control antibody (closed symbols) and restimu-
latedwith PBMC from the donors originally used for priming
showed a typical accelerated secondary proliferative response,
peaking on day 3. In contrast, those same primed cells showed
a typical primary response, peaking on day 6, when stimu-
lated with PBMC from a third-party donor. Cells primed
TCR-a//3
Figure 2.
￿
Reexpression ofCD3 and
TCR-a/,B moleculesaftermodulation
induced by anti-CD3. Cellswere cul-
tured in primaryMLC for 8 d in the
presence of 10 isg/ml of anti-CD3 an-
tibody BC3, washed andrecultured in
~
￿
medium containing no antibody. Cells
l( :, ---.,...-
￿
were stainedby direct immunofluores-
cenceimmediately after washing, time
defined day0(. . .), on day 1 (_ . _), day
2 (_ . . _), or day 3 (_ . . . _) with
FITC-conjugated antibody BC3 (left)
or C]33-a/,8-specific antibody WT31
(right). Negative controls (_ _) were
stained by anonbinding, isotype-matched
FITC-conjugatedantibody ofirrelevant
specificity. Positive controls (_) were
cells primed in thepresence of a non-
binding antibody.
104in the presence of antibody BC3 (open symbols), however,
showed no detectable response when challenged with PBMC
from the original donor, yet responded normally to PBMC
from a third-party donor. The degree of proliferation observed
in secondary MLC correlated with the concentration of anti-
body BC3 in the primary cultures, with 93% inhibition
achieved at 10 jAg/ml, and 73% inhibition at 1 14g/ml (data
not shown). These results demonstrate that the secondary
proliferative response of human T cells can be inhibited in
an antigen-specific manner when the primary culture with
alloantigen occurs in the presence of antibody BC3 at a con-
centration of 10 1~g/ml.
To assess whether the ability to induce alloantigen-specific
nonresponsiveness was unique for antibody BC3, other anti-
CD3 antibodies were tested in identical assays. Antibody 38.1
is a murine IgM anti-CD3 antibody that is not mitogenic
for human PBMC unless bound to a solid-phase matrix. An-
tibody 38.1 inhibited primary MLR by 85% when compared
with a control antibody of irrelevantspecificity (Table 2, line
2). Furthermore, cells exposed to alloantigen in primary MLC
in the presence of antibody 38.1 demonstrated a decreased
response to the specific antigen in restimulation assay, as low
Table 2.
￿
Efect of Anti-Lymphocyte Antibodies in Primary
MLC on T Cell Responses to Primary and Secondary
Stimulation by Alloantigen
Percent peak proliferative
control response
Primary cultures were performed in medium containing 10 wg/ml test
or control antibody. Secondarycultures were performedin medium con-
taining no antibody. 13H]TdRuptake was measured daily for 10 d and
cpm values at peak response were used to calculate percent ofthecontrol
proliferative response as described in Materials and Methods. The timing
of peak proliferation differed between primary and secondary MLCbut
wasidenticalforeach antibody tested. Thedistribution of the values shown
in the table is bimodalandvalues clustering around the lower mode are
reported in underscored characters.
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as 15% of control values, whereas response to a third-party
alloantigen was not affected. Antibody 64.1 is a murine IgG2a
anti-CD3 antibody that is mitogenic for human PBMC pre-
sumably by virtue of crosslinking the CD3 complex on T
cells with the Fc receptor type I (CD64) on monocytes (31,
32). The degree of proliferation of PBMC incubated with
antibody 64.1 was similar in response to either autologous
or allogeneic irradiated stimulators, so that the response to
the allogeneic stimulus was as low as 3% of control cultures
with no antibody (Table 2, line 3). Cells exposed to alloan-
tigen in the presence of antibody 64.1 had a decreased re-
sponse to the specific antigen in restimulation assay, as low
as 4% of control values, whereas response to third-party al-
loantigen was 45% ofcontrol values. Therefore, T cell non-
responsiveness to specific alloantigen was induced by three
distinct anti-CD3 antibodies regardless of their mitogenic
effect on T cells.
Secondary Purlferative Response ofLymphocytes Exposed to A1-
loantigen in the Presence ofAntibodies to OtherCell Surface Mol-
ecules. Certain antibodies specific for lymphocyte surface
receptors other than CD3 have profound effects on T cell
function. Antibodies against CD18 (the 0 chain of the leu-
kocyte function-associated antigen 1 [LFA-1 complex]) and
CD2 (LFA2) inhibited lymphocyte proliferation in primary
MLC (Table 2, lines 4, 5, and 6) but had no effect on kinetics
or magnitude of subsequent secondary proliferative responses
to specific or third-party alloantigens in absence of antibody.
Anti-CD28 antibody 9.3 and anti-CD4 antibody 66.1 in-
hibited primary MLR by 66% and 44%, respectively, but
had no effect on secondary proliferative responses in the ab-
sence of antibody (Table 2, lines 7 and 8) . Anti-CD5 anti-
body 10.2 and anti-CD8 antibody 51.1 did not inhibit pri-
mary or secondary MLR (Table 2, lines 9 and 10). Taken
together, these data indicate that anti-CD3 antibodies are
unique in their ability to induce nonresponsiveness to re-
stimulation with specific alloantigen in secondary cultures.
Duration ofAntigen-specific Nonresponsiveness Induced by Anti-
CD3. To assess the duration of alloantigen-specific non-
responsiveness, cells were exposed to alloantigen in medium
containing BC3 or control antibody, washed on day 8, and
cultured in fresh medium without antibody or alloantigen
for 4, 11, or 18 d. These cells were restimulated on days 12,
19, and 26, respectively, after initiation of the primary cul-
ture. At all time points, cells primed in medium containing
control antibody showed a typical accelerated proliferative
response, peaking on day 3, when restimulated with irradi-
ated PBMC from the donor originally used for priming and
showed a typical primary response, peaking on day 6, when
restimulated with irradiated PBMC from a third-party donor
(Fig. 3). In contrast, cells primed in the presence of anti-
CD3 antibody did not respond when stimulated with irradi-
ated PBMC from the original donor but remained capable
ofresponding to cells ofa third-party donor. These data dem-
onstrate that the nonresponsive state induced by exposure to
alloantigen in the presence of antibody BC3 appears to last
for at least 34 d afterinitiation of the culture and for at least
26 days after removal of the antibody.
Time RequiredforAnti=CD3 to Induce Nonresponsiveness.
￿
To
Anti-CD3 and Antigen Induce Specific Nonresponsiveness in Human T Cells
Antibody
primary
Specificity
added to
MLC
Clone
Primary
MLC
Secondary MLC
Specific Third-Party
antigen antigen
CD3 BC3 1 7 79
CD3 38 .1 15 15 135
CD3 64 .1 3 4 45
CD18 60.3 1 71 130
CD2 BC18 10 108 81
CD2 9.6 13 72 81
CD28 9.3 34 109 118
CD4 66.1 56 93 100
CD5 10.2 83 54 103
CD8 51 .1 92 60 122
Control 9E8 100 100 100Day 12
￿
Day 19
Days
Days
determine the duration of exposure to anti-CD3 necessary
for development of nonresponsiveness, cellswere washed on
days 1, 3, 5, or 7 of primary MLC, resuspended in fresh
medium without antibody, and rested until day 12 when they
were restimulated with irradiated PBMC from the original
donor or from a third-party donor. Primary MLC in the pres-
ence of antibody BC3 for 3, 5, or 7, but not for 1 d, pro-
duced nonresponsiveness in secondary cultures stimulated with
irradiated PBMC from the original donor and had no effect
on the response to irradiated PBMC from third-party donors.
Primary MLC carried out with antibody BC3 for 1 d had
diminishedthe magnitude of the secondary response to 68%
of the control (Fig. 4). Thus, it appears that the minimum
time of exposure to antibody BC3 needed to induce allo-
antigen-specific nonresponsiveness in MLC is between 1 and
3 d.
Effect ofAnti-CD3 on CTL Generation.
￿
Disparity for MHC
class II antigens induces proliferation of allogeneic T cells
in MLC, while disparity for MHC class I antigens induces
Figure 4.
￿
Time required for anti-CD3 to induce nonresponsiveness.
Respondercells primed with allogeneic stimulators in thepresence ofcon-
trol antibody (") or anti-CD3 for1 (0), 3("), 5 (O), or 7(A) dwere
restimulated with cells from the same donor(left) or a third-party donor
(right,uppertraces) or autologous cells (right,lonertraces: control antibody
[*], anti-CD3 for one [01, 3 ["], 5 [p], or 7 [A] d) in the absence
of antibody.
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Day 26
the generation of cytotoxic T cells. To determine whether
antibody BC3 added to the primary MLC could block the
generation ofCTL as well as cell proliferation, cultures were
set up in medium containing BC3 or control antibody for
5 d. These cells were washed, cultured in fresh medium
without antibody for 3 d, and then tested in a standard 4-h
"Cr-release cytotoxicity assay against target cells from the
specific donor. Antibody BC3 abrogated generation of CTL
(data not shown), a finding previously demonstrated for other
anti-CD3 antibodies (2). In subsequent experiments, cultures
containing BC3 or control antibody were maintained for
8 d, cells were washed and cultured in fresh medium without
antibody for 4 d. Cells were then restimulated with irradi-
ated PBMC from the original donor or from a third-party
donor and tested for cytolytic activity. Cells primed in the
presence of control antibody (closed symbols) were able to
generate cytotoxic activity when restimulated with cells of
both the original donor (Fig. 5, left) and the third-party donor
v
0 d
w
Ir-
O
Specific
Antigen
Control
Antigen
Figure 3.
￿
Duration of antigen-spe-
cific nomesponsiveness inducedby anti-
CD3. Respondercells primer with al-
logeneic stimulators in thepresence of
anti-CD3 (opensymbols) or control an-
tibody (closeds)mbols) were restimulated
at theindicatedtime points with cells
from the same donor (top) or a third-
party donor (bottom, squares), or with
autologous cells (bottom, circles) in the
absence of antibody.
Effector : Target Ratio
Figure 5.
￿
Effect of anti-CD3 on CTLgeneration. Respondercells were
primed in the presence of anti-CD3 (open circle) or nonbinding control
antibody (closedcircle) andthen restimulated with cells from thesame al-
logeneic donor (left) or from a third party donor (right) in the absence
of antibody. Cytotwdc activity againstT lymphoblasts from the respec-
tive donors was assayed on day 6 of the secondary cultures.M
O
a v
20
0 1 2 3 4 5 6 7 0 9 10
0 1 2 3 4 5 6 7 8 9 10
Days
SECONDARY MLR
Antibody Added:
a rnAb control
o mAb CD3
TERTIARY MLR
Antibody Washed:
11 mAb control
o mAb CD3
Figure 6.
￿
Effect ofanti-CD3 on responsiveness ofprimed cells. PBMC
were primed with allogeneic stimulators in absence of antibody (top).
Primed cells were restimulated in secondary MLR with cells from the
same donor (middle) in the presence of anti-CD3 (opensquare) or control
antibody (closedsquare). Cellsfrom respective bulk cultures were restimu-
lated in a tertiary MLR (bottom) with cells from the same donor in ab-
sence of the antibody.
Table 3.
￿
Effect of Anti-CD3 mAb on Generation ofCells with Suppressive Activity
(Fig. 5, right). In contrast, cells primed in the presence of
antibody BC3 (open symbols) did not generate cytotoxic ac-
tivity when restimulated with cells from the original donor
but remained capable of generating cytotoxic activity when
restimulated with cells from the third-party donor. Thus,
findings in the cytotoxicity assay paralleled those seen in the
proliferative assays.
Effect ofAnti-CD3 on Responsiveness ofPrimed Cells.
￿
Further
experiments were undertaken to determine whether allo-
antigen-specific nonresponsiveness could be induced in primed
cells. For these experiments, cells were primed in a 12-d MLC
in medium containing no antibody (Fig. 6, toppanel). Primed
cells were then incubated with BC3 or control antibody for
1 h at 37°C, and restimulated with cellsfrom the donor orig-
inally used for priming. Antibody BC3 completelyinhibited
the secondary proliferative response (Fig. 6, middle panel). In
separate cultures, primed cells were restimulated in the pres-
ence of BC3 or control antibody for 8 d, then washed and
rested for four additional days. Cells were then assayed in a
tertiary MLR. Antibody BC3 had had no effect on respon-
siveness ofprimed cells to restimulation with specific antigen
(Fig. 6, bottom panel). Thus, induction of nonresponsiveness
by antibody BC3 was seen only in unprimed and not in primed
cells.
Effect ofAnti-CD3 on Generation of Cells with Suppressive
Activity. During an in vitro MLC, certain cells acquire
antigen-specific suppressive activity (33). This can be demon-
strated by a reduced proliferation when primed irradiatedcells
are added to fresh autologous responders stimulated with
specific alloantigen. Suppressive activity is increased if the
priming MLC is carried out in the presence of cyclosporine
or antibodies binding to the IIr2 receptor (34, 35). We inves-
tigated whether cells primed to specific antigen in the pres-
ence of antibody BC3 had acquired this type of suppressive
activity. Cells recovered from primary MLC carried out in
the presence of antibody BC3 were irradiated and added as
regulators in a fresh MLC. Cells primed in the presence of
the anti ID2 receptor light chain antibody 2A3 (CD25) at
10 Ag/ml or cyclosporine A at 0.5 ug/ml suppressed the
Primary cultures were performed in medium containing 10 Kg/ml 9E8 (control), BC3 (anti-CD3), 2A3 (anti-CD25), or 0.5 ug/ml cyclosporine
A (CYA), mixing responder cells from one individual with irradiated stimulator cells from HLA incompatible donors A or B. Primed cells were
irradiated (1,500 rad) and tested as regulators in a fresh MLC. 1sH]thymidine uptake was measured daily for 10 dand cpm values at peak response
were used to calculate percent inhibition as described in Materials and Methods. No significant differences in response kinetics were observed for
antibody or CYA treated cultures (data not shown).
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Priming
Cell donor
Stimulating
Antibody 9E8
(negative control)
Percent inhibition
Antibody BC3
(anti-CD3)
Antibody 2A3
(anti-CD25) CYA
A A 32 34 87 93
A B 9 4 7 11
B B 32 20 85 88
B A 15 10 -10 0proliferative response of fresh autologous lymphocytes stimu-
lated with specific alloantigen but had no effect on the re-
sponse to alloantigen from third party donors (Table 3). In
contrast, cells primed in control cultures with an antibody
of irrelevant specificity had little specific suppressive activity.
Cells primed in the presence of anti-CD3 also showed little
specific suppressive activity. Thus, nonresponsiveness induced
by anti-CD3 antibody was not likely the result of activation
of a radiation-resistant suppressor cell.
Discussion
Our study demonstrates that co-stimulation with a soluble
anti-CD3 antibody and alloantigen can induce a sustained
stateof specific nonresponsiveness in unprimed human T cells.
One possible interpretation of this phenomenon is that modu-
lation of the TCRCD3 complex by a high concentration
of soluble anti-CD3 antibody can condition T cells to be-
come anergic in response to allogeneic MHC, a process that
might be similar to induction of anergy by excess antigen
(36, 37). We demonstrated nonresponsiveness in both prolifer-
ative as well as CTL generation assays, suggestingthat anti-
CD3 antibodies can condition the response of more than one
type of T cell to both MHC class I and class II alloantigens.
Lack of CTL generation, however, might merely reflect the
absence of helper activity and does not necessarily indicate
nonresponsiveness to MHC class I antigens.
Nonresponsiveness was inducible only by antibodies specific
for CD3 and not by antibodies to other T cell surface mole-
cules. LFA-1 (CD11/CD18) and LFA2 (CD2) are surface
receptors mediating antigen-independent intercellular adhe-
sion by binding to their respective ligands ICAM-1/2 and
LFA-3 expressed on a variety of all types. LFA1 and LFA-2
or associated structures, are capable of signal transduction
since antibodies to LFA1 and LFA2 not only can block cell
adhesion but also effect a variety of other cellular functions.
We have confirmed that anti-LFA1 and anti-LFA2 antibodies
inhibit primary MLR, but this does not affect the pattern
of secondary response to specific antigen. Results ofanti-LFA1
and LFA2 blocking experiments suggested that T cell memory
can be induced with little or no DNA synthesis. Thus, it
would seem unlikely that nonresponsiveness induced by anti-
CD3 antibodies results solely from insufficient cellular prolifer-
ation during primary antigen exposure.
The culture conditions we used were favorable for allowing
sustained T cell viability and function as measured by responses
to alloantigens for up to 26 d after initiation of the primary
culture. Nonresponsiveness to restimulation by the priming
antigen did not likely result from failure to reexpress the TCR
CD3 complex, since cells showed a uniform pattern ofTCR
and CD3 surface reexpression, that had returned to control
levels within 3 d ofculture in absence ofanti-CD3 antibody.
Lack of TCRCD3 reexpression on the small population of
clones specific for the priming antigens, however, could not
be excluded by our assay. We also attempted to rule out that
nonresponsiveness to the priming antigen was secondary to
activation of suppressor cells, which occurs in MLC. Cells
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able to suppress the proliferative response of unprimed autol-
ogous PBMC against specific alloantigen can be preferentially
activated in MLC carried out in the presence of cyclosporine
A or antibodies to the IIr2R 55-kD chain (34, 35). Cells
exposed to anti-CD3 and alloantigen were nonresponsive to
restimulation in secondary MLC, but had no detectable sup-
pressive effect when added to autologous responder PBMC
in a fresh MLC against specific alloantigen. By a process of
elimination, we suggest that T cell nonresponsiveness induced
by anti-CD3 antibody is likely the result of clonal anergy
or death. The MLC model cannot distinguish these two pos-
sibilities.
Use ofnonmitogenic murine anti-CD3 antibodies was es-
sential to achieve the results shown. Mitogenic anti-CD3 an-
tibodies also induced nonresponsiveness, although culture with
mitogenic anti-CD3 yielded lowercell viability, which might
in part account for the decreased secondary response against
cells from third-party donors. In addition, mitogenic anti-
CD3 antibodies by themselves might induce generalized T
cell hyporesponsiveness, as demonstrated by in vitro and in
vivo experiments in murine systems (11, 38). The mitogenic
activity of anti-CD3 antibodies depends on their heavy chain
isotype (39). Since Fc receptors on accessory cells provide a
matrix for multimeric binding of anti-CD3 antibodies, and
since crosslinking of CD3 molecules is one of the require-
ments for induction of DNA synthesis in T cells, the affinity
of Fc receptors on accessory cells for the Fc domain of anti-
CD3 antibodies represents an important determinant of T
cell activation. Fc receptors types I (CD64) are permissive
for the mitogenic activity of murine IgG2a and IgG3 anti-
CD3 antibody (31), while Fc receptors type II (CD32) are
permissive for murine IgG1 anti-CD3 antibodies (40). Fc
receptors type II on monocytes and B cells bind aggregated
murine IgG2b immunoglobulins, but this does not lead to
mitogenic activity, even though anti-CD3 IgG2b antibodies
are mitogenic when bound to a solid-phase support (40). This
may reflect the high flexibility of the hingeregion ofmurine
IgG2b immunoglobulins that allows the bound antigen to
move in multiple directions (41) .
The functional consequences of ligand. binding to TCR-
CD3 depend both on the physical properties of theinterac-
tion and the state of differentiation and activation of the T
cell. In immature thymocytes and in certain T cell tumor
lines, crosslinking TCRCD3 induces an increase in cyto-
plasmic free calcium followed by RNA and protein synthesis
(42). Cells increase in size but are blocked in progression
through the cell cycle at the interface between GI and S (43).
Activation of a calcium dependent endonuclease causes DNA
fragmentation and cell death, a phenomenon known as apop-
tosis (44-51). It has been suggested that clonal deletion of
autoreactive T cells in the thymus may occur by a similar
process (52). Variants ofa murine T cell hybridoma expressing
normal amounts of CD3r2 but decreased amounts of
CD3rq demonstrated little activation ofa serine-specificpro-
tein kinase that phosphorylates CD3y (45). In contrast to
the parental line, the variants did not undergo programmed
cell deathafterCD3 crosslinking (50). In this and in another
model (53), the biological responses ofT cells seemed to de-pend on the composition of the TCRCD3 complex. In view
of this observation, it is attractive to question whether the
TCR-CD3 complex on human T cells undergoes structural
changes aftera soluble anti-CD3 has induced internalization
of the TCR-CD3-ligand complex.
In contrast to lymphocytes freshly separated from periph-
eral blood, we couldnot induce nonresponsiveness in T cells
previously primed in vitro. Profound differences have been
identified between "naive" and "memory" T cells (54).
Memory T cells can be distinguished by their increased ex-
pression of LFA1, LFA-2, LFA-3, ICAM-1, CD29, and
CD45RO, whereas naive T cells have low or undetectable
expression of these molecules, and instead, express high levels
of CD45RA. During in vitro priming, T cells stimulated
by alloantigen lose the cell surface phenotype of naive T cells
and acquire a phenotype characteristic.of memory T cellsand
requirements for further cellular activation change (55).
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